<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889834</url>
  </required_header>
  <id_info>
    <org_study_id>K180405J</org_study_id>
    <nct_id>NCT03889834</nct_id>
  </id_info>
  <brief_title>Biological Parameters Changes After Autologous Blood Transfusion of Red Blood Cells (200 ml) in Healthy Volunteers.</brief_title>
  <acronym>AUTOT-SPORT</acronym>
  <official_title>Modification of Biological Parameters After Autologous Blood Transfusion of a Small Volume of Packed Red Blood Cells (200 ml) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Anti-Doping Agency (AFLD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Anti-doping Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GR-Ex executive comitee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Transfusion Sanguine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if differences between samples of subjects obtained&#xD;
      before autologous blood transfusion or samples of non-transfused subjects and samples of&#xD;
      subjects after autologous blood transfusion can be identified. Analyses performed will focus&#xD;
      on the morphological and biochemical parameters of red blood cells and associated&#xD;
      microparticles. The final goal would be to find markers of autologous blood transfusion, that&#xD;
      could be used to identify such doping practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology and study design:&#xD;
&#xD;
      Pr Olivier Hermine, coordinator of the laboratory of Excellence GR-EX regrouping EFS&#xD;
      (Etablissement Français du Sang) and INTS (Institut National de Transfusion Sanguine)&#xD;
      partners, and leader of the Centre d'Investigation Clinique (CIC) IMAGINE (Hospital Necker,&#xD;
      Paris, France) will assure the promotion of the clinical study for Paris Hospital consortium&#xD;
      AP-HP (assistance Publique-Hôpitaux de Paris).&#xD;
&#xD;
      To reproduce two potential scenarios of autologous transfusion by an athlete, 1 bag of blood&#xD;
      packed red blood cells (after leuko deprivation and centrifugation) will be either stored at&#xD;
      4°C or frozen at -80°C after addition of 40% w/v glycerol. Reinfusion will be performed 31&#xD;
      days later.&#xD;
&#xD;
      A clinical randomized double-blinded two-phase study will be conducted. Volunteers will be&#xD;
      separated in 3 groups:&#xD;
&#xD;
        -  Group 1: Volunteers with regular sports activities without Autologous Blood Transfusion&#xD;
           (ABT)T (n=10)&#xD;
&#xD;
        -  Group 2: Volunteers with regular sports activities receiving a 200ml ABT with&#xD;
           refrigerated blood (n=10)&#xD;
&#xD;
        -  Group 3: Volunteers with regular sports activities receiving a 200ml ABT with frozen&#xD;
           blood (n=10)&#xD;
&#xD;
      To ensure volunteers safety, collection, preparation and pretransfusion blood testing will be&#xD;
      performed by EFS at hospital Pitié-Salpêtrière (Paris, France). ABT as well as collection of&#xD;
      samples will be performed at the IMAGINE Institute (Paris, France). Blood samples will be&#xD;
      collected before blood removal, the day of the ABT just before reinfusion and after 3 hours,&#xD;
      8 hours, 24 hours and 48 hours post-ABT. To perform all the experiments 25ml blood (4x 5 ml&#xD;
      BD Vacutainer EDTA tubes) will be taken at each time point:&#xD;
&#xD;
      1 will be dispatched to the French anti-doping laboratory for haematological analysis&#xD;
      (Châtenay-Malabry, France), 2 to the EFS (Créteil, France) for RBC and MPs morphological&#xD;
      characterization and quantification (using antigen markers, band 3 on the surface of MPs), 2&#xD;
      to INTS for MPs isolation, characterization (band 3 on the surface of MPs and RBC) and for&#xD;
      proteomic analysis and Western-Blot.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>erythrocytes (/µL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>hemoglobin (g/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>Hematocrit (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>Mean corpuscular volume (fL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>Reticulocyte by Sysmex XT2000i analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation in Red blood cells morphology</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>By amnis imaging flow cytometryProteins in Red blood cells (Wblot/ELISA/FACS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in expression of cell surface proteins in red blood cells transfusion</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>Western blot /ELISA/ fluorescence-activated cell sorting of red blood cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in microparticles detected in plasma</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>fluorescence-activated cell sorting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in phthalate in urine</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>Assay by LC-MS/MS in urine</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>The Focus is on the Detection of the Consequences of Autologous Blood Transfusion in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Autotransfusion: blood stored at 4 ° C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at 4 ° C for 31 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autotransfusion: blood stored at -80°C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at -80°C for 31 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls not transfused</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>no transfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Blood Transfusion</intervention_name>
    <description>Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days</description>
    <arm_group_label>Autotransfusion: blood stored at -80°C</arm_group_label>
    <arm_group_label>Autotransfusion: blood stored at 4 ° C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No transfusion</intervention_name>
    <description>no transfusion</description>
    <arm_group_label>Controls not transfused</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male between 18 and 35 years old&#xD;
&#xD;
          -  Without health problem nor disease requiring regular medical treatment&#xD;
&#xD;
          -  free from any intercurrent acute pathology over 7 days&#xD;
&#xD;
          -  healthy volunteers who have regularly sport activity, able to have blood sample and is&#xD;
             out-of-competition during the research&#xD;
&#xD;
          -  Subject who did not practiced a competition (or exhaustive training ) 3 days before&#xD;
             the blood sample and the autotransfusion&#xD;
&#xD;
          -  Affiliated to a social security regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - subject with contraindication for drawing blood&#xD;
&#xD;
          -  Subject with medical pathology contraindicating sport practice - Subject under&#xD;
             treatments or drugs in the Prohibited List updated each year by the World Anti-Doping&#xD;
             Agency.&#xD;
&#xD;
          -  Subject with physical or mental disability or restriction of liberty that would&#xD;
             prevent autotransfusion&#xD;
&#xD;
          -  Subject without to a social security regimen&#xD;
&#xD;
          -  Subject under guardianship or curatorship&#xD;
&#xD;
          -  Subject participating in any Interventional study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier Hermine, MD</last_name>
    <phone>+33 (0)1 44 49 51 98</phone>
    <email>olivier.hermine@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie Jolaine, Manager</last_name>
    <phone>: +33 (0)1 42 19 28 79</phone>
    <email>valerie.jolaine@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Etablissement Français du Sang IDF, Hôpital de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <state>IDF</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre Gameiro, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous transfusion</keyword>
  <keyword>doping</keyword>
  <keyword>blood markers</keyword>
  <keyword>detection</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

